2/9
08:04 am
esla
Estrella Immunopharma (NASDAQ:ESLA) had its "buy" rating reaffirmed by analysts at D. Boral Capital. They now have a $8.00 price target on the stock.
High
Report
Estrella Immunopharma (NASDAQ:ESLA) had its "buy" rating reaffirmed by analysts at D. Boral Capital. They now have a $8.00 price target on the stock.
2/9
07:00 am
esla
Estrella Immunopharma Presents Promising Updated Data on EB103 in Oral Presentation at the 2026 Tandem Meetings of ASTCT® & CIBMTR®
High
Report
Estrella Immunopharma Presents Promising Updated Data on EB103 in Oral Presentation at the 2026 Tandem Meetings of ASTCT® & CIBMTR®
2/3
08:00 am
esla
Estrella Immunopharma Announces Late-Breaking Oral Presentation of Phase 1 STARLIGHT-1 Data for EB103 at the 2026 Tandem Meetings of ASTCT® & CIBMTR®
Medium
Report
Estrella Immunopharma Announces Late-Breaking Oral Presentation of Phase 1 STARLIGHT-1 Data for EB103 at the 2026 Tandem Meetings of ASTCT® & CIBMTR®
1/31
01:33 am
esla
Estrella Immunopharma (NASDAQ:ESLA) was upgraded by analysts at
Wall Str
Low
Report
Estrella Immunopharma (NASDAQ:ESLA) was upgraded by analysts at
Wall Str
1/30
06:05 am
esla
Estrella Immunopharma (NASDAQ:ESLA) had its "sell (d-)" rating reaffirmed by analysts at
Weiss Ratings.
Medium
Report
Estrella Immunopharma (NASDAQ:ESLA) had its "sell (d-)" rating reaffirmed by analysts at
Weiss Ratings.
1/28
08:04 am
esla
Estrella Immunopharma (NASDAQ:ESLA) had its price target lowered by analysts at D. Boral Capital from $16.00 to $8.00. They now have a "buy" rating on the stock.
Low
Report
Estrella Immunopharma (NASDAQ:ESLA) had its price target lowered by analysts at D. Boral Capital from $16.00 to $8.00. They now have a "buy" rating on the stock.
1/17
01:11 am
esla
Estrella Immunopharma (NASDAQ:ESLA) was downgraded by analysts at
Wall S
Medium
Report
Estrella Immunopharma (NASDAQ:ESLA) was downgraded by analysts at
Wall S
1/6
02:02 pm
esla
Estrella Immunopharma Announces Closing of $8.0 Million Registered Direct Offering and Concurrent Private Placement
Medium
Report
Estrella Immunopharma Announces Closing of $8.0 Million Registered Direct Offering and Concurrent Private Placement
1/5
08:30 am
esla
Estrella Immunopharma, Inc. Announces $8.0 Million Registered Direct Offering and Concurrent Private Placement Priced At-the-Market Under Nasdaq Rules
Medium
Report
Estrella Immunopharma, Inc. Announces $8.0 Million Registered Direct Offering and Concurrent Private Placement Priced At-the-Market Under Nasdaq Rules
12/4
08:00 am
esla
Estrella Advances STARLIGHT-1 Trial into Phase II Following Positive DSMB Recommendation
Medium
Report
Estrella Advances STARLIGHT-1 Trial into Phase II Following Positive DSMB Recommendation
11/22
02:11 am
esla
Estrella Immunopharma (NASDAQ:ESLA) was upgraded by analysts at
Wall Str
High
Report
Estrella Immunopharma (NASDAQ:ESLA) was upgraded by analysts at
Wall Str
11/22
02:11 am
esla
Estrella Immunopharma (NASDAQ:ESLA) was upgraded by analysts at
Wall Str
High
Report
Estrella Immunopharma (NASDAQ:ESLA) was upgraded by analysts at
Wall Str